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Background
Effective determinations of sample size require interaction between
statisticians and their research collaborators who wish to initiate
studies. The majority of grant applications, clinical trial protocols,
and IRB submissions will not be approved unless there is some
statistical justification for the planned sample size that is appropriate
for the study’s primary objective [1]. However, obtaining a suitable
sample size is non-trivial and may necessitate dynamic conversations
regarding aims, objectives, study design, and future directions. Such
conversations may address the types of data to be collected, analytic
plans, and whether the specified endpoints and objectives will answer
the goals of the study post-completion.

meeting, a statistician may find it helpful to ask collaborators for a fiveminute synopsis of their overall study goals. From that, a statistician
may readily identify the overarching aims of the study and help the
collaborator to word them precisely but succinctly. However, further
information may be required to ascertain what type of data should be
collected. Asking questions may help to clarify this. Examples include:
1. “How often and for how long will you follow up with your
subjects to obtain endpoints?”
2. “How do you imagine the data looking at the end of the trial?”
3. “If your aim is to show that a particular treatment is better, what
information do we need to collect to definitively achieve this aim?”

Beyond meeting the challenge of satisfying reviewers, a wellinformed sample size justification will ensure reasonable precision in
estimation and adequate statistical power for hypothesis tests. Such
a justification is also made in the context of proposing a budget and
assessing feasibility of the study design. The sample size must be
sufficient to test the primary objective and large enough to obtain
preliminary data for secondary objectives and correlative studies;
but an excessive sample size may be seen as wasteful and perhaps
even unethical, if unnecessarily many subjects are randomized to an
ineffective treatment. This editorial, based in part on the authors’ own
real-world experiences, is directed to statisticians and will highlight
some important factors to consider and discuss with collaborators to
ensure proper study design, endpoint collection, and sample size. Some
such factors may be easy to overlook, even for a statistician, while some
pertain to finding common ground with scientists whose statistical
training may be limited.

For oncological and other clinical trials, endpoints differ by each
phase in drug development. Phase I trials aim to assess safety and
identify an appropriate dose; consequently, the corresponding endpoint
must be, or at least encompass, a toxicity outcome [3]. These studies are
typically single arm, non-randomized trials whose results are analyzed
mainly with descriptive statistics rather than formal hypothesis tests.
Phase II studies look for hints of efficacy that would warrant Phase III
trials. Phase II trials often assess surrogate endpoints, clinical response
rates, and percentages of patients that “succeed” with the treatment, as
defined for a particular trial prior to its initiation. They can be single
arm studies with historical control comparisons, but recently there has
been a call for randomized Phase II trials [4]. In Phase III trials, the goal
is to show definitive clinical benefit with a head-to-head comparison
involving at least two groups, which ordinarily requires time-to-event
endpoints such as disease progression, mortality, heart attack or stroke,
and so forth.

Outcomes and Objectives

Statisticians can help investigators to ensure that their aims match
the appropriate phase of drug development. In fact, statisticians may
occasionally help collaborators planning a Phase II study to realize that
a Phase I trial ought to be conducted first. This may be the case when,
for example, the referenced dose is unsuitable for the targeted patient
population or not yet tested in combination with another drug.

All research proposals begin with aims. The primary objective
will influence all aspects of a study, including but not limited to
data collection, sample size, design, and analytic plans. Therefore,
the primary objective is an excellent starting point for discussions
between statisticians and collaborators, as specifying succinct aims and
appropriate endpoints will drive the rest of the design process.

Aims versus endpoints
Sometimes a collaborator may struggle with identifying aims and
corresponding endpoints. An outcome measure, also called an endpoint,
relates to the parameter of interest in a study aim; however, outcomes
are not synonymous with aims. An outcome is a patient-level measure
of effect. Ideally, endpoints should be valid and reliable, quantifiable,
easy to observe, free of measurement error, capable of being observed
independently of the treatment assignment, and clinically relevant [2].
Aims must be clear, concrete, and inclusive of outcomes that can be
measured in a realistic timeframe. They must be more specific than
whether the treatment “works”; one question to ask is, “How will
you determine that treatment is effective and worth future research
for your patient population?” Writing a hypothesis can also help to
clarify an aim and guide the analytic plan. During an introductory
J Biomet Biostat
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Primary outcomes
Virtually all studies will have multiple questions; however, the
primary question should be the most clinically important and will
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drive the study design. Ideally, a single response variable should be
identified to answer the primary question [5]. If more than one is used,
the probability of getting a nominally significant result by chance alone
is increased, unless one incorporates a multiplicity correction; but then
statistical power is sacrificed.

Secondary aims and correlatives
Secondary aims are important but do not drive design. In
phase I trials, these can include descriptions of pharmacokinetics,
pharmacodynamics, or preliminary clinical responses. In phase II
studies, secondary objectives can be to estimate overall survival,
describe safety, evaluate changes in biomarkers, assess quality of
life measures, or address subsidiary questions relating to a patient
subgroup. However, all secondary aims should be specified before
data collection and limited in number. Moreover, principles similar
to those previously articulated still apply for writing secondary aims
and determining corresponding outcomes. Relevant questions for a
statistician to discuss with a collaborator may include:
1. “What is the biologic rationale for these additional aims?”
2. “Will samples collected come from biopsy tissue or blood, and if
so is collection of patient samples in a pre-post design feasible?”
3. “Will the additional effort to acquire these endpoints add to the
scientific knowledge gained from your study, and is the effort worth the
time, money, and resources?”
Additionally, sketching an excel spreadsheet shell may be helpful
to see what data the investigators plan to collect (regardless of what
data management program will be used). Since researchers are
generally familiar with excel, such a sketch can provide a springboard
for discussing which outcomes are most critical, how often they will
be measured, how they will be categorized, and so forth. This step can
help researchers to visualize how their data will look at the end of the
trial and may identify data collection needs that have been overlooked.

Sample Size Considerations
The basics
After the aims are specified and corresponding endpoints identified,
sample size calculations may commence; however, there are many
factors to consider. The three basic components include alpha, beta,
and delta (clinically relevant difference), as detailed in Table 1. Alpha is
chosen a priori and typically set to 0.05. In phase II clinical trial or pilot
studies, some investigators will set alpha=0.10 or 0.15, although this is
not as common [4].
Definition

What does this mean
clinically?

Alpha-α
Probability of rejecting
(Type I Error probability) the null hypothesis when
Significance Level of
it is true
a test

Superiority Setting-Falsely
claiming a difference

Beta-β
(Type II Error probability)
Complementary to
power of a test

Probability of failing
to reject a false null
hypothesis

Superiority Setting-Falsely
claiming no difference

Delta-δ (Minimum
Clinically Relevant
Difference or CRD)

What is the minimum
treatment effect that
would ultimately change
clinical practice?

Superiority-lower bound
on efficacy advantage of
treatment

Non-inferiority Setting-Falsely
claiming a similarity

Non-inferiority Setting-Falsely
claiming a difference

Non-inferiority-upper bound
on efficacy disadvantage of
treatment

Table 1: Basic components for sample size calculations.
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Power is equal to 1-beta and is typically set to 80% (or sometimes
90% for confirmatory studies). If power is too low, then there is little
chance of rejecting the null even if the alternative is true, which
is potentially disastrous given that substantial resources are often
invested in a study. Assuming that the clinically relevant difference has
not been mis-specified (see next paragraph), the cause of low power is
inadequate sample size [6]. Perhaps counter intuitively, one may also
have power that is too high. For instance, doubling the sample size
starting from 50% power may lead to 79% power, whereas doubling
the sample size starting from 98% power may yield 99.99% power.
Since one was already very unlikely to commit a Type II error at 98%
power, the doubling of that sample size may be seen as wasteful and
even unethical.
The minimum clinically relevant difference (CRD or delta) is
often the most difficult piece of information to obtain pre-study. The
minimum CRD relates specifically to the primary endpoint. Depending
on the variable type, this can be a percentage, mean (expressed relative
to a corresponding standard deviation), median (expressed relative to
a corresponding range or inter-quartile range), or hazard ratio. The
minimum CRD can sometimes be informed by pilot data or other
published studies, but in any case there must be a clinical justification:
what treatment effect would ultimately change clinical practice [7]?
Importantly, statistical significance does not imply clinical significance,
and therefore the minimum CRD may not be what was observed
previously. Of course, investigators sometimes have little or no pilot
data to inform specification of the minimum CRD. In such cases, a
statistician may aid them by sketching suitable diagrams. For instance,
Figure 1 depicts two partially overlapping bell curves corresponding to
two different choices of the minimum CRD for a normally distributed
endpoint. Then investigators may select which, if either, diagram they
think may represent a realistic expectation for the data they intend to
collect.

Types of endpoints
Among several other possibilities, endpoints can be continuous,
binary, or time-to-event. There are pros and cons to each type, and
some study designs will naturally favor one type over the others.
Nonetheless, this choice will influence both the sample size calculation
and the selection of statistical methodology for the data analysis plan.
Categorical data are easy to describe and interpret, but caution is
required because such data usually require greater sample sizes. For
example, a binary outcome can only be a “0” or a “1”, so variability
between groups is thereby limited. In fact, there is usually a substantial
loss of power when inherently continuous data are categorized.
Additionally, there is potential ambiguity in the selection of cut points
for such categorizations, which may preclude comparisons across or
meta-analysis of related studies [8].

Number of groups
When there are two or more groups, the investigators need to
decide upon randomization, blinding, and treatment allocation.
Regarding the latter, the most practical option is usually 1:1 group
allocation, as this generally yields optimal or near-optimal power
for the total sample size. However, there are some situations where
assigning more subjects to a new procedure may enhance enrollment
and mitigate ethical concerns about exposing subjects to a riskier or
potentially less effective treatment.
For continuous outcomes with at least three groups, there are
sample size formulas for the ANOVA F test. However, the investigator's
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Figure 1: Example of bell curves to visualize minimum CRD.

may also wish to incorporate some type of imputation into the data
analysis plan.

Parametric assumptions

Decrease
Alpha ↓

Increase
Power ↑

Sample
size
increase↑

Decrease
minimum
CRD ↓

Conducting a
2-sided test
versus 1sided

Decrease
Follow-up
time and/or
accrual time
↓

Figure 2: Factors that cause sample size to increase when keeping all other
considerations constant.

true interest usually lies in the post-hoc comparisons between specific
groups. A statistician calculating a sample size to power a post-hoc
comparison must take into account the Bonferroni or other adjustment
for multiple such comparisons. This is unfortunately easy to overlook,
and failing to take into account such an adjustment may result in
grossly underpowered comparisons between specific groups.

Withdrawals and non-compliance
Missing outcome data may arise when subjects are lost to follow
up, withdraw consent, die, or refuse to answer. There are also situations
in which subjects (or even study personnel) do not comply with the
treatment or protocol. If missing outcome data are anticipated, then
sample size estimates should be adjusted accordingly. For instance, if
20% of subjects are anticipated to drop out, then sample size estimates
should be inflated by a minimum of 25%. In such a case, a statistician
J Biomet Biostat
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Also important, both to sample size calculations and to
development of the data analysis plan, are discussions of assumptions
for parametric tests. This is because nonparametric tests usually
have less statistical power than parametric tests. Thus, choosing a
sample size in anticipation of a parametric test and discovering later
that a nonparametric test is required will lead to an underpowered
comparison. Reviewing literature from other studies that use similar
outcomes can be very helpful to assess whether the need for a
nonparametric test is at least somewhat likely. If so, then inflating the
sample size by 10-15% a priori may be a good idea.
Even for parametric tests, there may be some pitfalls to using
standard sample size formulas. For instance, when employing a T test
to compare two groups on a continuous outcome, the usual sample size
formula actually involves quantiles of a Z distribution. They are meant
to approximate quantiles of a T distribution, but the degrees of freedom
for that T distribution are unknown since they depend on the sample
size that one is trying to determine. If investigators hope to justify a
sample size in the neighborhood of 5 to 15, this Z approximation to a
T quantile may result in unexpectedly low power. As a practical rule of
thumb, adding two subjects per group to whatever answer is obtained
with the Z approximation works surprisingly well.

Conclusion
The study aims and corresponding outcome measurements influence
all other aspects of study design, including sample size calculations
and formulation of a statistical analysis plan. As shown in Figure 2,
altering simply one factor within a study design can cause the sample
size to change significantly. Writing aims well is challenging because
an investigator must convince readers that the aims are both achievable
and worthwhile. A further challenge emerges because the process of
study design is not always linear. For instance, upon completion of a
sample size calculation, an investigator may change his/her aims to
avoid prohibitive expenses [2]. Likewise, accrual limitations may have
implications for study design. Ongoing interactions among the entire
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research team, including the statistician(s), can provide solutions, or at
least alternatives, when difficulties arise. Beyond that, statisticians must
also help investigators to avoid common errors, such as those described
above and one other noted by Kramer and Kupfer [9]: “One common
mistake in [study design] is guaranteeing adequate power, not at or
above the threshold of clinical significance, but at or above the desired
or hoped-for effect size or one based on very optimistic, underpowered,
pilot studies.” Taking time prior to study initiation to discuss objectives
and sample sizes is critical, since a poorly designed study cannot be
fixed and may not even be salvageable post-completion [10].
Acknowledgements
This editorial was supported by the National Center for Research Resources,
UL1RR033173, National Center for Advancing Translational Sciences,
UL1TR000117, and the National Cancer Institute, P30CA177558. The content
is solely the responsibility of the authors and does not necessarily represent the
official views of the NIH.

References
1. Schulz KF, Grimes DA (2005) Sample size calculations in randomised trials:
mandatory and mystical. Lancet 365: 1348-1353.
2. Garrett-Mayer E (2012) Statistical Considerations in Protocol Development:

From Hypothesis to Analysis. Proceedings of AACR/ASCO Methods in Clinical
Cancer Research Workshop. Vail, CO.
3. Ivy SP, Siu LL, Garrett-Mayer E, Rubinstein L (2010) Approaches to phase
1 clinical trial design focused on safety, efficiency, and selected patient
populations: a report from the clinical trial design task force of the national
cancer institute investigational drug steering committee. Clin Cancer Res 16:
1726-1736.
4. Rubinstein L, Crowley J, Ivy P, Leblanc M, Sargent D (2009) Randomized
phase II designs. Clin Cancer Res 15: 1883-1890.
5. Pocock SJ (1997) Clinical trials with multiple outcomes: a statistical perspective
on their design, analysis, and interpretation. Control Clin Trials 18: 530-545.
6. Wang D1, Bakhai A1, Buono AD2, Maffulli N3 (2013) Sample size determination
for clinical research. Muscles Ligaments Tendons J 3: 116-117.
7. Farrokhyar F, Reddy D, Poolman RW, Bhandari M (2013) Why perform a priori
sample size calculation? Can J Surg 56: 207-213.
8. Royston P, Altman DG, Sauerbrei W (2006) Dichotomizing continuous
predictors in multiple regression: a bad idea. Stat Med 25: 127-141.
9. Kraemer HC, Kupfer DJ (2006) Size of treatment effects and their importance
to clinical research and practice. Biol Psychiatry 59: 990-996.
10. Clark T, Berger U, Mansmann U (2013) Sample size determinations in original
research protocols for randomised clinical trials submitted to UK research
ethics committees: review. BMJ 346: 1135.

Submit your next manuscript and get advantages of OMICS
Group submissions
Unique features:
•
•
•

User friendly/feasible website-translation of your paper to 50 world’s leading languages
Audio Version of published paper
Digital articles to share and explore

Special features:

Citation: Van Meter E, Charnigo R (2014) Strengthening Interactions between
Statisticians and Collaborators: Objectives and Sample Sizes. J Biomet Biostat
5: e127. doi:10.4172/2155-6180.1000e127

J Biomet Biostat
ISSN: 2155-6180 JBMBS, an open access journal

•
•
•
•
•
•
•
•

300 Open Access Journals
25,000 editorial team
21 days rapid review process
Quality and quick editorial, review and publication processing
Indexing at PubMed (partial), Scopus, EBSCO, Index Copernicus and Google Scholar etc
Sharing Option: Social Networking Enabled
Authors, Reviewers and Editors rewarded with online Scientific Credits
Better discount for your subsequent articles

Submit your manuscript at: http://www.editorialmanager.com/biobiogroup/

Volume 5 • Issue 1 • 1000e127

